Journal article
Igg against plasmodium falciparum variant surface antigens and growth inhibitory antibodies in mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine
D Quelhas, A Jiménez, L Quintó, E Serra-Casas, A Mayor, P Cisteró, L Puyol, DW Wilson, JS Richards, T Nhampossa, E Macete, P Aide, I Mandomando, S Sanz, JJ Aponte, PL Alonso, JG Beeson, C Menéndez, C Dobaño
Immunobiology | ELSEVIER GMBH | Published : 2011
Abstract
This study aimed to evaluate whether intermittent preventive treatment in infants with sulfadoxine-pyrimethamine (IPTi-SP) had an effect on the acquisition of IgG against Plasmodium falciparum variant surface antigens (VSA) and growth-inhibitory antibodies in Manhiça, Mozambique. In addition, we assessed factors affecting the magnitude of these responses and the association between antibody levels and protection against malaria. IgG to VSA expressed by MOZ2, R29 and E8B parasite isolates were measured in plasma samples collected at 5, 9, 12 and 24 months of age by flow cytometry. Growth-inhibitory antibodies in dialyzed plasmas using GFP-D10 parasites were measured by flow cytometry at 12 an..
View full abstractGrants
Awarded by Bill and Melinda Gates Foundation
Funding Acknowledgements
We are grateful to the study children and their mothers and families, and the staff at the Manhica District Hospital. We thank Joe Campo, Cleofe Romagosa, Gerardo Cabrera, Lazar Quimice, Nelito Jose, Ana Rosa Manhica, and Joanne Chesson for technical support. We thank Dr. C. Chitnis (ICGEB, New Delhi) for providing us with the R29 parasite line and Dr. A. Cortes (IRB, Barcelona) for providing us with the E8B parasite line. We also thank Robin Anders and Mick Foley (WEHI, Melbourne) for allowing the use of the 1F9 monoclonal antibody. This work was supported by the Bill and Melinda Gates Foundation (grant IPTi103-0) and the Banco de Bilbao, Vizcaya, Argentaria Foundation (grant BBVA 02-0). CD is supported by the Ministerio de Ciencia e Innovacion (RYC-2008-02631), DQ was supported by WHO/TDR (grant OD/TS-07-00017), AM was supported by Institut de Salud Carlos III (CP-04/00220), and JGB, JSR, and DWW were supported by the National Health and Medical Research Council of Australia. The Centro de Investigacao em Saude da Manhica receives core support funding from the Spanish Agency for International Cooperation and Development (AECID).